Megan E Piper1, Christopher Bullen2, Suchitra Krishnan-Sarin3, Nancy A Rigotti4, Marc L Steinberg5, Joanna M Streck6, Anne M Joseph7. 1. Center for Tobacco Research and Intervention of Wisconsin, Department of Medicine, School of Medicine and Public Health, University of Wisconsin, Madison, WI. 2. National Institute for Health Innovation, School of Population Health, University of Auckland, Auckland, New Zealand. 3. Department of Psychiatry, Yale University School of Medicine, New Haven, CT. 4. Department of Medicine, Massachusetts General Hospital, Boston, MA. 5. Division of Addiction Psychiatry, Rutgers University, New Brunswick, NJ. 6. Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA. 7. Department of Medicine, University of Minnesota, Minneapolis, MN.
Abstract
BACKGROUND: Changes in tobacco products, use patterns, and assessment technology in the last 15 years led the Society for Research on Nicotine and Tobacco (SRNT) Treatment Research Network to call for an update to the 2003 SRNT recommendations for assessing abstinence in clinical trials of smoking cessation interventions. METHODS: The SRNT Treatment Research Network convened a group of investigators with decades of experience in conducting tobacco treatment clinical trials. To arrive at the updated recommendations, the authors reviewed the recommendations of the prior SRNT Workgroup as well as current literature. Ten additional experts in the field provided feedback on this paper and these recommendations. RESULTS: With respect to defining abstinence, the authors recommend: (1) continuing to use the definition of no use of combustible tobacco products (regardless of use of noncombustible tobacco products [e.g., snus] and alternative products [e.g., e-cigarettes]) and collecting additional data to permit alternate abstinence definitions; (2) no use of combustible or smokeless tobacco products; and (3) no use of combustible or smokeless tobacco products or alternative products, as appropriate for the research question being addressed. The authors also recommend reporting point prevalence and prolonged abstinence at multiple timepoints (end of treatment, ≥3 months after the end of treatment, and ≥6 months postquit or posttreatment initiation). CONCLUSIONS: Defining abstinence requires specification of which products a user must abstain from using, the type of abstinence (i.e., point prevalence or continuous), and the duration of abstinence. These recommendations are intended to serve as guidelines for investigators as they collect the necessary data to accurately describe participants' abstinence during smoking cessation clinical trials. IMPLICATIONS: This paper provides updated recommendations for defining abstinence in the context of smoking cessation treatment clinical trials.
BACKGROUND: Changes in tobacco products, use patterns, and assessment technology in the last 15 years led the Society for Research on Nicotine and Tobacco (SRNT) Treatment Research Network to call for an update to the 2003 SRNT recommendations for assessing abstinence in clinical trials of smoking cessation interventions. METHODS: The SRNT Treatment Research Network convened a group of investigators with decades of experience in conducting tobacco treatment clinical trials. To arrive at the updated recommendations, the authors reviewed the recommendations of the prior SRNT Workgroup as well as current literature. Ten additional experts in the field provided feedback on this paper and these recommendations. RESULTS: With respect to defining abstinence, the authors recommend: (1) continuing to use the definition of no use of combustible tobacco products (regardless of use of noncombustible tobacco products [e.g., snus] and alternative products [e.g., e-cigarettes]) and collecting additional data to permit alternate abstinence definitions; (2) no use of combustible or smokeless tobacco products; and (3) no use of combustible or smokeless tobacco products or alternative products, as appropriate for the research question being addressed. The authors also recommend reporting point prevalence and prolonged abstinence at multiple timepoints (end of treatment, ≥3 months after the end of treatment, and ≥6 months postquit or posttreatment initiation). CONCLUSIONS: Defining abstinence requires specification of which products a user must abstain from using, the type of abstinence (i.e., point prevalence or continuous), and the duration of abstinence. These recommendations are intended to serve as guidelines for investigators as they collect the necessary data to accurately describe participants' abstinence during smoking cessation clinical trials. IMPLICATIONS: This paper provides updated recommendations for defining abstinence in the context of smoking cessation treatment clinical trials.
Authors: Kathryn L Taylor; Randi M Williams; Tengfei Li; George Luta; Laney Smith; Kimberly M Davis; Cassandra A Stanton; Raymond Niaura; David Abrams; Tania Lobo; Jeanne Mandelblatt; Jinani Jayasekera; Rafael Meza; Jihyoun Jeon; Pianpian Cao; Eric D Anderson Journal: J Natl Cancer Inst Date: 2022-10-06 Impact factor: 11.816
Authors: Jamie S Ostroff; Elyse R Park; Brett M Goshe; Autumn W Rasmussen; Lynne I Wagner; JoRean D Sicks; Ilana F Gareen; Ruth C Carlos; Benjamin A Herman; Angela Wangari Walter; Susan Regan; Douglas E Levy; Irene Mahon; Alona Muzikansky; Jordan M Neil; Michelle Lui; Deepika Dilip; Laura Malloy; Irina Gonzalez; Lucy Finkelstein-Fox; Caitlin McCann; Elissa Perez Journal: BMC Public Health Date: 2022-07-15 Impact factor: 4.135
Authors: Elyse R Park; Giselle K Perez; Susan Regan; Alona Muzikansky; Douglas E Levy; Jennifer S Temel; Nancy A Rigotti; William F Pirl; Kelly E Irwin; Ann H Partridge; Mary E Cooley; Emily R Friedman; Julia Rabin; Colin Ponzani; Kelly A Hyland; Susan Holland; Sarah Borderud; Kim Sprunck; Diana Kwon; Lisa Peterson; Jacob Miller-Sobel; Irina Gonzalez; C Will Whitlock; Laura Malloy; Suhana de León-Sanchez; Maureen O'Brien; Jamie S Ostroff Journal: JAMA Date: 2020-10-13 Impact factor: 56.272
Authors: Yong Cui; Jason D Robinson; Rudel E Rymer; Jennifer A Minnix; Paul M Cinciripini Journal: Nicotine Tob Res Date: 2022-01-01 Impact factor: 4.244
Authors: Andrew H Rogers; Justin M Shepherd; Julia D Buckner; Lorra Garey; Kara Manning; Michael F Orr; Norman B Schmidt; Michael J Zvolensky Journal: Drug Alcohol Depend Date: 2020-02-19 Impact factor: 4.492
Authors: E Jennifer Edelman; James Dziura; Yanhong Deng; Krysten W Bold; Sean M Murphy; Elizabeth Porter; Keith M Sigel; Jessica E Yager; David M Ledgerwood; Steven L Bernstein Journal: Contemp Clin Trials Date: 2021-03-29 Impact factor: 2.226